Exploring Idiopathic Myopathies #EULAR2026: Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune diseases with significant morbidity. While EULAR/ACR classification criteria were established in 2017, updated real-world data and better tools to assess https://t.co/CbUWodWT7z

What’s New in Psoriatic Arthritis: A Whirlwind Tour At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/IzsSzx6Pc9

Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA The approach to treating peripheral SpA has remained the same for a long time. The guidelines recommend starting with NSAIDs, escalating to conventional synthetic DMARDs, typically sulfasalazine or methotrexate, and https://t.co/iEqzp6FStv

Day 2 Report from EULAR 2026 Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2 https://t.co/6KwtkMNLAf https://t.co/Toh4HNZFN5

Are we failing in the treatment of RA-ILD? Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026. https://t.co/3UpQQE22Nz https://t.co/ULdCOgh7pY

RA-ILD: Screening risk and genetic susceptibility Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development. https://t.co/VoY3HFjbjf https://t.co/vPzLvBAWKJ

MRI as a novel biomarker in lupus The clinical abstract sessions at #EULAR2026 on diagnostic tools in lupus showcased interesting studies, including the use of MRI, as potential non-invasive biomarkers. https://t.co/TK2gqSxAg5 https://t.co/5Qj8KXWgub

Three Abstracts That May Shape the Future of RA Treatment Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an https://t.co/CaMSHlkbFD

Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA The approach to the treatment of peripheral SpA has been the same for a long time. The guidelines recommend starting with NSAIDs, escalate to conventional synthetic DMARDs, typically sulfasalazine or methotrexate and https://t.co/pG9dGSfgcP

Making Methotrexate More Effective Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London https://t.co/HfzSPVbcBl https://t.co/n6FKX34j8p

SLE Pipeline of New Therapies Dr. Andrea Fava, EULAR 2026 in London. https://t.co/GwntaPwzWr https://t.co/prFnaSKuqF

Treat to Target Works in Elderly Onset RA Dr. Jiha Lee reports on abstract POS1326 at EULAR 2026 in London https://t.co/X4vhR9KofC https://t.co/TSquFmZJCP